|Bid||114.29 x 800|
|Ask||114.32 x 1000|
|Day's Range||113.61 - 114.85|
|52 Week Range||75.28 - 114.85|
|PE Ratio (TTM)||52.26|
|Earnings Date||Oct 24, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||1.48 (1.30%)|
|1y Target Est||104.69|
Roughly 175 million Europeans have obstructive sleep apnoea, according to a late-breaking abstract presented by ResMed today at the European Respiratory Society’s annual ERS Congress in Paris. Leading researchers estimate 90 million Europeans have moderate to severe sleep apnoea, meaning they experience at least 15 breathing events an hour during sleep. These statistics are based on the latest scoring rules for determining one’s apnoea–hypopnoea index (AASM 2012) and are connected with a 16-country study announced in May 2018 that revealed an estimated 936 million people worldwide have sleep apnoea, a chronic sleep-disordered breathing condition associated with increased risk of mortality and reduced quality of life.
According to GuruFocus list of 52-week highs , these Guru stocks have reached their 52-week highs. Warning! GuruFocus has detected 4 Warning Sign with COL. Rockwell Collins Inc. is an aviation and high-integrity solutions company serving commercial and military customers.
Medical device maker Fisher & Paykel Healthcare said on Tuesday it had filed a patent infringement complaint against California-based Resmed, alleging it infringed five of its patents related to sleep apnea devices. The company said in a statement that it sought an exclusion order from the U.S. International Trade Commission (ITC) to prevent the importation and sale of Resmed's AirFit P10 range of nasal pillows masks in the United States. Last week, Fisher & Paykel cut its fiscal 2019 earnings guidance over expected legal costs from its tiff with Resmed.
Medical device maker Fisher & Paykel Healthcare said on Tuesday it had filed a patent infringement complaint in the United States against ResMed . The company said it sought an exclusion order from the ...
New Zealand medical device firm Fisher & Paykel Healthcare Corp cut its fiscal 2019 net profit outlook on Monday on the back of expected legal costs to contest patent allegations made by ResMed Inc. The firm said it would contest the patent allegations made against it by ResMed in the U.S. International Trade Commission (ITC) and U.S. District Court for the Southern District of California.
ResMed Inc (NYSE:RMD) files its latest 10-K with SEC for the fiscal year ended on June 30, 2018. ResMed Inc is a part of the healthcare sector.
In June 2018, ResMed Inc (NYSE:RMD) released its earnings update. Generally, analysts seem highly optimistic, as a 56.80% rise in profits is expected in the upcoming year, compared with theRead More...
ResMed (RMD) delivered earnings and revenue surprises of 5.56% and 1.18%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The San Diego-based company said it had profit of 76 cents per share. Earnings, adjusted for amortization costs and non-recurring costs, were 95 cents per share. The results topped Wall Street expectations. ...
SAN DIEGO-- -- Revenue increased 12% to $623.6 million; up 10% on a constant currency basis Net income increased by 8%; non-GAAP net income up 24% GAAP diluted earnings per share of $0.76; non-GAAP diluted earnings per share of $0.95 Operating cash flow of $129.4 million in the fourth quarter Quarterly dividend increased by 6% to $0.37 per share ResMed Inc. today announced results for its quarter ended ...
ResMed (RMD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
ResMed (RMD) is likely to keep its winning streak alive with a gain from strong performances on the domestic as well as global front in Q4.
On Thursday, July 19, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Healthcare equities this morning: OraSure Technologies Inc. (NASDAQ: OSUR), ResMed Inc. (NYSE: RMD), OpGen Inc. (NASDAQ: OPGN), and Organovo Holdings Inc. (NASDAQ: ONVO). On Thursday, shares in Bethlehem, Pennsylvania-based OraSure Technologies Inc. recorded a trading volume of 373,287 shares.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding RMD totaled $1.12 billion.
Medical device firm ResMed reported its fourth-quarter earnings. The company's president, Rob Douglas, weighs in on the company's performance and business strategy moving forward.